Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug996 | Community interest message Wiki | 0.41 |
| drug1040 | Control message Wiki | 0.41 |
| drug1870 | ISIS 721744 Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug288 | Angiography Wiki | 0.41 |
| drug1337 | Economic benefit message Wiki | 0.41 |
| drug3562 | Self-interest message Wiki | 0.41 |
| drug2630 | Not bravery message Wiki | 0.41 |
| drug4439 | consultation Wiki | 0.41 |
| drug3662 | Sodium Nitrite Wiki | 0.41 |
| drug4097 | Trust in science message Wiki | 0.41 |
| drug287 | Anger message Wiki | 0.41 |
| drug2874 | Personal freedom message Wiki | 0.41 |
| drug1368 | Embarrassment message Wiki | 0.41 |
| drug1669 | Guilt message Wiki | 0.41 |
| drug3165 | QFR Wiki | 0.41 |
| drug3597 | Seroprevalence of SARS-CoV-2 infection in patients with HIV infection Wiki | 0.41 |
| drug1338 | Economic freedom message Wiki | 0.41 |
| drug3475 | SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted) Wiki | 0.41 |
| drug523 | Baseline message Wiki | 0.41 |
| drug3408 | SAB-185 Wiki | 0.29 |
| drug3470 | SEL-212A Wiki | 0.29 |
| drug3405 | Ruxolitinib Oral Tablet Wiki | 0.29 |
| drug3471 | SEL-212B Wiki | 0.29 |
| drug3618 | Siltuximab Wiki | 0.24 |
| drug421 | Azithromycin Wiki | 0.07 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D023921 | Coronary Stenosis NIH | 0.41 |
| D006562 | Herpes Zoster NIH | 0.41 |
| D006073 | Gout NIH | 0.29 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003327 | Coronary Disease NIH | 0.15 |
| D007511 | Ischemia NIH | 0.14 |
| D003324 | Coronary Artery Disease NIH | 0.14 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.10 |
| D009203 | Myocardial Ischemia NIH | 0.09 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.09 |
| D008171 | Lung Diseases, NIH | 0.08 |
| D012140 | Respiratory Tract Diseases NIH | 0.08 |
| D055370 | Lung Injury NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.07 |
| D012141 | Respiratory Tract Infections NIH | 0.07 |
| D014777 | Virus Diseases NIH | 0.04 |
| D013577 | Syndrome NIH | 0.04 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0005145 | Coronary artery stenosis HPO | 0.41 |
| HP:0001997 | Gout HPO | 0.29 |
| HP:0001677 | Coronary artery atherosclerosis HPO | 0.14 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001658 | Myocardial infarction HPO | 0.09 |
| HP:0002088 | Abnormal lung morphology HPO | 0.08 |
| HP:0011947 | Respiratory tract infection HPO | 0.07 |
Navigate: Correlations HPO
There are 6 clinical trials
This multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of intravenous Sodium Nitrite Injection for treatment of patients infected with COVID-19 who develop lung injury and require mechanical ventilation.
Description: Proportion of study subjects who are alive and free of respiratory failure at Day 28
Measure: Survival with Unassisted Breathing Time: Day 28Description: Number of days alive without mechanical ventilation from start of study through Day 28
Measure: Survival without Mechanical Ventilation Time: Day 28Description: Number of days alive and not in the intensive care unit from start of study through Day 28.
Measure: Survival without Intensive Care Time: Day 28Description: Number of days alive and not in hospital from start of study through Day 28.
Measure: Survival without Hospitalization Time: Day 28Description: Alive on Day 28 and no use of ECMO therapy any time between start of study and Day 28.
Measure: Survival without ECMO Time: Day 28Description: Alive on Day 28
Measure: Survival Time: Day 28Description: Oxygenation index (PaO2/FIO2) at Day 14
Measure: Lung Status Time: Day 14Description: Blood urea nitrogen (BUN) at Day 14
Measure: Kidney Status (1) Time: Day 14Description: Creatinine at Day 14
Measure: Kidney Status (2) Time: Day 14Description: Liver function tests (ALT and AST) at Day 14
Measure: Liver Status Time: Day 14: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic [Tc] bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluate the safety, immunogenicity, and pharmacokinetics of SAB-185 in ambulatory participants with COVID-19.
Description: Incidence and severity of other adverse events and severe adverse events (SAE)
Measure: Number of Participants Having Adverse Events Time: 29 DaysDescription: transfusion-related adverse events
Measure: Number of Participants Having Transfusion-Related Adverse Events Time: 29 DaysDescription: Incidence and severity of adverse events and SAEs from Screening through Study Day 90
Measure: Number of Participants Having Adverse Events Time: 90 DaysDescription: Measurement of SARS CoV-2 neutralizing (PRNT80) antibody titers from screening through Study Day 90
Measure: Assesment of the PD of SAB-185 administered intravenously Time: 90 DaysDescription: Measurement of Rheumatoid factor through day 90
Measure: Immune response elicited by SAB-185 Time: 90 DaysDescription: Measurement of anti-SAB-185 antibodies through screening day 90
Measure: Concentration of subject anti-SAB-185 antibodies elicited by SAB-185 Time: 90 DaysDescription: Incidence of SARS-CoV-2 in swab specimens as measured by quantitative RT-PCR through Study Day 29
Measure: Incidence of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens Time: 29 DaysDescription: Level of SARS-CoV-2 in swab specimens as measured by quantitative RT-PCR through Study Day 29
Measure: Level of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens Time: 29 DaysThis is one of two replicate randomized, double-blind, placebo-controlled, parallel arm trials to determine the safety and efficacy of two different dose levels of SEL-212 compared to placebo. Approximately 105 patients, stratified as to the presence or absence of tophi, will be randomized in a 1:1:1 allocation ratio prior to Baseline to receive treatment with one of two dose levels of SEL-212 or placebo every 28 days for approximately 6 months in each trial (SEL-212/301 and SEL-212/302). Analysis of efficacy will be performed at Day 28 of Treatment Period 6. Safety will be monitored throughout the study.
Description: The percentage of patients who achieve and maintain reduction in serum uric acid (sUA) < 6 mg/dL for at least 80% of the time during month 6 in patients with gout refractory to conventional treatment treated with two different dose levels of SEL-212 compared to placebo
Measure: Serum uric acid control during month 6 Time: 6 monthsDescription: To assess changes in number of tender and swollen joints in patients with gout refractory to conventional treatment treated with two different dose levels of SEL-212 compared to placebo
Measure: Tender and Swollen Joint Counts Time: 6 monthsDescription: To assess change in tophus burden by photographic area assessment in patients with gout refractory to conventional treatment treated with two different dose levels of SEL-212 compared to placebo
Measure: Tophus burden Time: 6 monthsDescription: To assess change in Patient Reported Outcomes (PROs) including assessments of: activity limitation (HAQ-DI) in patients with gout refractory to conventional treatment treated with two different dose levels of SEL-212 compared to placebo
Measure: HAQ-DI Time: 6 monthsDescription: To assess change in Patient Reported Outcomes (PROs) including assessments of: patients' quality of life (QoL) (SF-36) in patients with gout refractory to conventional treatment treated with two different dose levels of SEL-212 compared to placebo
Measure: SF-36 Time: 6 monthsDescription: To assess changes in gout flare incidence in patients with gout refractory to conventional treatment treated with two different dose levels of SEL-212 compared to placebo
Measure: Gout Flare Incidence Time: 6 monthsThe purpose of this study is to measure the effect of the Shingrix vaccine on your immune system and whether that has any effect on the body's ability to fight off other infections such as COVID-19. We hypothesize that: H1: Shingrix vaccination will elevate acute and trained immunity H2: For 6 months following the first injection, increased levels of acute and trained immunity is associated with less disease, including fewer hospitalizations and deaths associated with flu, pneumonia, and COVID-19.
Description: The primary outcome is change in the release of Type I interferon, interferon gamma, interferon associated molecules, and proinflammatory mediators released from monocytes/macrophages and natural killer cells (including gene activation) after receiving 2 injections of the Shingrix vaccine versus normal saline.
Measure: Evidenced of active and trained innate immunity Time: Day 61 and 90 (post vaccination)Description: cases ( nasal swab for viral antigen and antibody testing), symptoms (symptom checklist), hospitalizations (MDS 3.0 report/chart reviews) and deaths (MDS 3.0 report/chart reviews) associated with flu, pneumonia, and COVID-19.
Measure: Respiratory Disease Severity (6 month) Time: Days 90 through 180Up to 1/3 of all patients infected with COVID-19 can develop complications that require hospitalization. Severe pneumonia associated with acute respiratory distress syndrome (ARDS) is the most threatening and feared complication of COVID-19 infection, with mortality rates close to 50% in some groups. Autopsies between these severe cases reveal severe capillary involvement, with signs of intense inflammatory changes, microvascular thrombosis, endothelial injury and abnormal tissue repair. The available evidence suggests that abnormal activation or imbalance in the counter-regulation of the kallikrein-kinin system may play a central role in a positive feedback cycle, leading to consequent diffuse microangiopathy. Blockade of the kallikrein-kinin system can therefore prevent deterioration of lung function by reducing inflammation, edema and microthrombosis. The objective of this phase IIb study is to assess the preliminary effects on the oxygenation parameters of an antisense oligonucleotide that inhibits pre-kallikrein synthesis in patients with moderate to severe COVID-19.
Description: Number of days the patient is alive and not receiving any supplementary respiratory support (oxygen, non-invasive ventilation, high flow nasal catheter or mechanical ventilation) during 15 days
Measure: Days alive without respiratory support (any supplemental oxygen) after 15 days (DAFOR15) Time: 15 daysDescription: Sequential Organic Failure Assessment [SOFA]. This will be a primary secondary outcome. Analysis will check for trends in SOFA up to 15 days in a single model.
Measure: SOFA - Sequential Organ Failure Assessment Score up to 15 days after randomization Time: 15 daysDescription: Intubation and initiation of mechanical ventilation for any given reason
Measure: Need for mechanical ventilation Time: 30 days (or until hospital discharge)Description: Number of days the patient remains in mechanical ventilation
Measure: Duration of mechanical ventilation Time: 30 days (or until hospital discharge)Description: Daily oxygenation levels assessed using the ROX index [(Oxygen Saturation/Inspired Fraction)/Respiratory Rate] from randomization to discharge or day 14, whichever comes first.
Measure: Oxygenation index Time: 14 daysDescription: C-reactive protein levels over time up to 15 days or hospital discharge.
Measure: C-reactive protein levels during first 15 days after randomization Time: 15 daysDescription: Lymphocyte/neutrophil ratio over time up to 15 or until discharge discharge day.
Measure: Lymphocyte/neutrophil ratio during first 15 days after randomization Time: 15 daysDescription: D-dimer serum levels over time or until hospital discharge.
Measure: D-dimer serum level during first 15 days after randomization Time: 15 daysDescription: Fibrinogen serum levels over time up to 15 days or until hospital discharge
Measure: Fibrinogen serum levels during first 15 days after randomization Time: 15 daysDescription: Prothrombin Time over time up to 15 days or until hospital discharge.
Measure: Prothrombin Time levels during first 15 days after randomization Time: 15 daysDescription: Activated Partial Thromboplastin Time over time up to 15 days or until hospital discharge.
Measure: Activated Partial Thromboplastin Time during first 15 days after randomization Time: 15 daysDescription: One-year all cause mortality
Measure: Mortality Time: 1 year after randomizationDescription: Quality of Life measured by EQ-5D from 11111-33333, lower values being better
Measure: Euroquol questionnaire for quality of life with 5 dimensions (EQ-5D) Time: 1 year after randomizationThis study will evaluate the efficacy and safety of siltuximab compared with normal saline in combination with standard of care (SOC) in selected hospitalized patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection associated with acute respiratory distress syndrome (ARDS) and elevated C-reactive protein (CRP) levels.
Description: 28-day all-cause mortality
Measure: 28-day all-cause mortality Time: Day 28Description: Time to 7-category ordinal scale of clinical status improvement (T7COSCSI)
Measure: Time to 7-category ordinal scale of clinical status improvement (T7COSCSI) Time: Up to 60 daysDescription: Ventilator-free days (VFDs) within 28 days
Measure: Ventilator-free days (VFDs) within 28 days Time: Up to 28 daysDescription: Organ failure-free days (OFFD)
Measure: Organ failure-free days (OFFD) Time: Up to 60 daysDescription: Intensive care unit length of stay (ICU LOS)
Measure: Intensive care unit length of stay (ICU LOS) Time: Up to 60 daysDescription: Hospital length of stay (HLOS)
Measure: Hospital length of stay (HLOS) Time: Up to 60 daysDescription: In-hospital all-cause mortality (IHACM)
Measure: In-hospital all-cause mortality (IHACM) Time: Up to 60 daysDescription: 60-day all-cause mortality (60DACM)
Measure: 60-day all-cause mortality (60DACM) Time: Up to 60 daysDescription: Time to oxygenation improvement (TOI)
Measure: Time to oxygenation improvement (TOI) Time: Up to 60 daysDescription: Duration of supplemental oxygen (DSO)
Measure: Duration of supplemental oxygen (DSO) Time: Up to 60 daysDescription: Chest radiographic improvement (CRI)
Measure: Chest radiographic improvement (CRI) Time: Up to 60 daysDescription: Time to National Early Warning Score 2 improvement (TNEWS2I)
Measure: Time to National Early Warning Score 2 improvement (TNEWS2I) Time: Up to 60 daysDescription: Treatment-emergent adverse events (TEAEs)
Measure: Treatment-emergent adverse events (TEAEs) Time: Up to 60 daysDescription: Plasma siltuximab concentrations (PSCs)
Measure: Plasma siltuximab concentrations (PSCs) Time: Up to 60 daysDescription: Anti-siltuximab antibodies (ASA)
Measure: Anti-siltuximab antibodies (ASA) Time: Up to 60 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports